指数尾盘翻红，编制方案“提纯”今日落地，恒生创新药ETF（159316）全天净申购达1000万份

Core Insights - The Hong Kong innovative drug sector experienced a rebound, with Fosun Pharma and Hutchison China MediTech both rising over 2%, contributing to the positive performance of the Hang Seng Innovative Drug Index [1] - CITIC Securities forecasts a favorable pharmaceutical policy environment supporting innovative drug development from 2025 onwards, recommending investment in three areas: innovation-driven strategies, internationalization, and reforms in outpatient marketing models [1] - The Hang Seng Innovative Drug Index underwent a revision to exclude CXO companies, focusing solely on innovative drug firms, resulting in a "pure" index that has shown an annualized return of 47% since its launch on July 10, 2023 [1] Industry Summary - The Hang Seng Innovative Drug ETF (159316) recorded a trading volume exceeding 400 million yuan and net subscriptions of 10 million units, indicating strong market interest [1] - The revised index is the first to achieve 100% purity in tracking innovative drug companies, enhancing its ability to capture investment opportunities in the sector [1] - The Sharpe ratio of the index has improved post-adjustment, suggesting better risk-adjusted returns for investors [1]